Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04423484

Therapeutic Recommendations for Nephroblastoma

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nephroblastoma Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplastic Syndromes, Hereditary Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms Wilms Tumor

Age range

6 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso

Loading trial locations.

About this study

The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.

.

Exclusion criteria

Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal

Treatment and study plan

Data Collection

Other

Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.

Primary outcomes

  1. Evaluation of the number of cases with local disease.

    Time frame: 5 years

    By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.

  2. Evaluation of the number of cases with stage IV disease.

    Time frame: 5 Years

    By evaluating the initial clinical reports and later histological reports to confirm the stage.

  3. Evaluating the treatment given.

    Time frame: 5 Years

    Comparison of treatment given and recommended treatment.

  4. Evaluating the follow up after treatment.

    Time frame: 5 Years

    How many children alive or dead after treatment

Secondary outcomes

  1. Why has treatment failed

    Time frame: 5 years

    look at precision of reporting by comparing reports (histological and surgical)

Study contacts

Contact information is provided by the study sponsor or research team.

BRENDA Ms MALLON, MSC

CONTACT

[email protected]

0033142115411

Sponsors and collaborators

Lead sponsor

French Africa Pediatric Oncology Group

Other

Registry information

Official study title

Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.

Acronym: GFANEPHRO20

Important dates

Study start
2020
Primary completion
2028
Study completion
2030
First posted
Jun 9, 2020
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.